These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29245952)

  • 21. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
    Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
    Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are anti-Müllerian hormone and its receptor polymorphism associated with the hormonal condition of undescended testes?
    Komarowska MD; Milewski R; Charkiewicz R; Matuszczak E; Sulewska A; Zelazowska-Rutkowska B; Hermanowicz J; Niklinski J; Debek W; Hermanowicz A
    Adv Med Sci; 2016 Sep; 61(2):288-292. PubMed ID: 27162065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ovarian response to standard gonadotropin stimulation is influenced by AMHRII genotypes.
    Lazaros L; Fotaki A; Pamporaki C; Hatzi E; Kitsou C; Zikopoulos A; Virgiliou C; Kosmas I; Bouba I; Stefos T; Theodoridis G; Georgiou I
    Gynecol Endocrinol; 2016 Aug; 32(8):641-645. PubMed ID: 26933946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural mutations of the anti-Mullerian hormone type II receptor found in persistent Mullerian duct syndrome affect ligand binding, signal transduction and cellular transport.
    Belville C; Maréchal JD; Pennetier S; Carmillo P; Masgrau L; Messika-Zeitoun L; Galey J; Machado G; Treton D; Gonzalès J; Picard JY; Josso N; Cate RL; di Clemente N
    Hum Mol Genet; 2009 Aug; 18(16):3002-13. PubMed ID: 19457927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
    Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
    Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Anti-Mullerian hormone and ovarian cancer.
    La Marca A; Volpe A
    Hum Reprod Update; 2007; 13(3):265-73. PubMed ID: 17213257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Müllerian hormone (AMH): regulator and marker of ovarian function.
    van Houten EL; Themmen AP; Visser JA
    Ann Endocrinol (Paris); 2010 May; 71(3):191-7. PubMed ID: 20362961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of prenatal exposure to diethylstilbestrol on Müllerian duct development in fetal male mice.
    Visser JA; McLuskey A; Verhoef-Post M; Kramer P; Grootegoed JA; Themmen AP
    Endocrinology; 1998 Oct; 139(10):4244-51. PubMed ID: 9751506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive negative regulation in the processing of the anti-Müllerian hormone receptor II.
    Hirschhorn T; di Clemente N; Amsalem AR; Pepinsky RB; Picard JY; Smorodinsky NI; Cate RL; Ehrlich M
    J Cell Sci; 2015 Apr; 128(7):1352-64. PubMed ID: 25663701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
    Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors.
    Rey R; Sabourin JC; Venara M; Long WQ; Jaubert F; Zeller WP; Duvillard P; Chemes H; Bidart JM
    Hum Pathol; 2000 Oct; 31(10):1202-8. PubMed ID: 11070112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
    Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
    Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.
    Salhi I; Cambon-Roques S; Lamarre I; Laune D; Molina F; Pugnière M; Pourquier D; Gutowski M; Picard JY; Xavier F; Pèlegrin A; Navarro-Teulon I
    Biochem J; 2004 May; 379(Pt 3):785-93. PubMed ID: 14750901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The anti-mullerian hormone--physiology and application into clinical practice].
    Robeva R; Mekhandzhiev Ts; Tomova A; Kumanov F
    Akush Ginekol (Sofiia); 2006; 45(7):50-4. PubMed ID: 17489169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
    Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels.
    Panidis D; Katsikis I; Karkanaki A; Piouka A; Armeni AK; Georgopoulos NA
    Med Hypotheses; 2011 Oct; 77(4):649-53. PubMed ID: 21807466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.